BRIDGEWATER, N.J., March 10, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company focused on putting people first, aims to provide top-quality treatments for patients with serious illnesses. Today, the company announced that it has given inducement awards to 18 new staff members.
Look into Insmed's (INSM) global revenue trends and how they affect Wall Street's predictions and the potential future of the stock.
INSM reported a larger loss in the fourth quarter than anticipated. However, it has confirmed its sales forecast for Arikayce in 2025, expecting it to be between $405 million and $425 million.
Insmed (INSM) reported a quarterly loss of $1.32 per share, which is worse than the Zacks Consensus Estimate of a $1.15 loss. This is also a decline from the loss of $1.28 per share recorded a year earlier.
Insmed Incorporated (INSM) has released the transcript for their Q4 2024 earnings call.
Baron Funds, an investment management firm, published its fourth quarter 2024 investor letter for the "Baron Health Care Fund." The Fund's performance was similar to the Benchmark, despite a tough quarter for the overall health care sector. You can download the letter here, which notes that the fund fell by 9.58% (Institutional Shares) during the quarter.
Insmed (INSM) has the right mix of two important factors that could lead to a strong earnings report soon. Be ready for the main expectations.
On February 11, 2025, Insmed Incorporated, a biopharmaceutical company focused on improving patient lives, announced that its management will speak at upcoming investor conferences. They will present at the 45th Annual TD Cowen Healthcare Conference in Boston on March 3, 2025, at 9:10 a.m.
BRIDGEWATER, N.J., Feb. 10, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company focused on putting people first, aims to provide top-quality treatments for patients with serious illnesses. The company has announced that it will share its financial results for the fourth quarter and the entire year of 2024 on Thursday, February 20, 2025.
The FDA has approved a priority review for INSM's New Drug Application (NDA) for brensocatib, which is intended for patients with non-cystic fibrosis bronchiectasis. A decision on this application is expected by August 12, 2025.